DNase I as Treatment for MPO-ANCA Vasculitis

DNase I 治疗 MPO-ANCA 血管炎

• 批准号: nhmrc : GNT1146892
• 负责人: Dr Poh Yi Gan
• 金额: $ 86.83万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/dnase-i-treatment-anca-vasculitis/1348792
• 关键词: DNase; Treatment; MPO; ANCA; Vasculitis

MPO-ANCA GN is a major cause of renal failure. Current treatments are toxic and poorly effective. Excessive DNA production resulting in prominent deposits of extracellular DNA are seen in glomeruli of patients with MPO-ANCA GN. This study will look at the pathological role of DNA and in a relevant animal model, use DNase I treatment to dissolve deposited DNA and treat anti-MPO autoimmunity and GN. This evidence will allow the introduction of DNase I in clinical trials.

MPO-ANCA GN是肾衰竭的主要原因。目前的治疗是有毒的，效果不佳。在MPO-ANCA GN患者的肾小球中观察到导致细胞外DNA显著沉积的过量DNA产生。本研究将着眼于DNA的病理作用，并在相关的动物模型中，使用DNase I治疗溶解沉积的DNA并治疗抗MPO自身免疫和GN。这一证据将允许在临床试验中引入DNA酶I。